ProCE Banner Activity

Key Questions in Targeted Therapy for Biliary Tract Cancer

Clinical Thought

In this commentary, experts discuss key questions from a webinar focused on recent advances in targeted therapy for advanced biliary tract cancer.

Released: April 15, 2024

Expiration: April 14, 2025

Share

Faculty

Mitesh J. Borad

Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

Lipika Goyal

Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Disclosure

Primary Author

Mitesh J. Borad, MD

Professor of Medicine
Mayo Clinic College of Medicine and Science
Phoenix, Arizona

Mitesh J. Borad, MD: consultant/advisor/speaker: Merck, Servier; researcher: Relay.

Lipika Goyal, MD, MPhil

Associate Professor in Medicine
Director of Gastrointestinal Oncology
Stanford School of Medicine
Palo Alto, California

Lipika Goyal, MD, MPhil: researcher (paid to institution): Alyssum Therapeutics, Genentech; consultant/advisor: AbbVie, Alentis Therapeutics AG, AstraZeneca, Black Diamond, Exelixis, Genentech, Incyte, Kinnate, Merck, QED, Servier, Sirtex Medical, Surface Oncology, Taiho Oncology, TransThera Bio, Tyra Biosciences; data and safety monitoring board: AstraZeneca.